XC221 200 mg

DRUG3 trials

Sponsors

PHARMENTERPRISES LLC, Valenta Pharm JSC

Conditions

Acute Respiratory InfectionAcute Respiratory Viral InfectionsAcute Viral Upper Respiratory InfectionsInfluenzaViral Respiratory Infection

Phase 1

Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers

CompletedNCT03459391

PHARMENTERPRISES LLCAcute Respiratory Infection, Influenza

Start: 2017-05-22End: 2017-09-26Updated: 2018-03-08

Phase 2

Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections

CompletedNCT03455491

PHARMENTERPRISES LLCAcute Respiratory Viral Infections, Influenza

Start: 2018-02-12End: 2018-06-28Updated: 2019-11-04

A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

CompletedNCT05030324

Valenta Pharm JSCAcute Viral Upper Respiratory Infections, Influenza, Viral Respiratory Infection

Start: 2021-10-01End: 2022-05-04Updated: 2023-07-27